Levonorgestrel Intrauterine System (LNG-IUS) is the Most Effective Birth Control for Heavy, Painful Periods
For heavy menstrual bleeding with pain, the levonorgestrel intrauterine system (LNG-IUS, brand name Mirena®) is the superior contraceptive option, demonstrating greater efficacy than combined oral contraceptives and other hormonal methods. 1, 2
Primary Recommendation: LNG-IUS (Mirena®)
The LNG-IUS releases levonorgestrel locally for 5 years and provides the most substantial reduction in menstrual blood loss among all contraceptive options 3. When directly compared to combined oral contraceptives (COCs), the LNG-IUS was significantly more effective at reducing menstrual blood loss (OR 0.21,95% CI 0.09 to 0.48) 1. This translates to a dramatic improvement in both bleeding volume and pain symptoms.
Key advantages:
- Reduces menstrual blood loss by up to 90% over time
- Many women develop amenorrhea (no periods) after the first year, which is medically safe 4
- Provides highly effective contraception (>99% efficacy)
- Decreases dysmenorrhea (painful periods) significantly
- Lasts 5 years with minimal maintenance
Expected bleeding pattern: Counsel patients that irregular spotting or light bleeding is common during the first 3-6 months, but this decreases substantially with continued use. Heavy or prolonged bleeding is uncommon with LNG-IUS 4.
Second-Line Option: Combined Oral Contraceptives (COCs)
If LNG-IUS is not acceptable or contraindicated, COCs are the next best option. Specifically, estradiol valerate/dienogest (brand name Natazia®) has FDA approval for treating heavy menstrual bleeding and demonstrated an 81% median reduction in blood loss volume 5.
Standard COCs with a step-down estrogen and step-up progestogen regimen also effectively reduce menstrual blood loss, increasing treatment success from 3% (placebo) to 12-77% 1. COCs containing ≤35 μg ethinyl estradiol are recommended 4, 6.
Alternative COC formulations:
- Monophasic pills (same hormone dose daily)
- Extended or continuous regimens (fewer or no hormone-free days) to reduce bleeding episodes 7
- Vaginal ring (NuvaRing®) releasing ethinyl estradiol and etonogestrel 4
- Transdermal patch (Evra®) 4
Important caveat: COCs carry increased venous thromboembolism (VTE) risk, particularly with third-generation progestins (desogestrel, gestodene), drospirenone, and cyproterone acetate compared to second-generation progestins (levonorgestrel, norgestimate) 3. Avoid in women with VTE risk factors.
Third-Line: Progestin-Only Pills (POPs)
For women who cannot use estrogen-containing methods (due to VTE risk, migraine with aura, breastfeeding, etc.), progestin-only options are appropriate:
- Norethindrone (various brands)
- Desogestrel (Cerazette®)
- Drospirenone (Slynd®) - showed reduced unscheduled bleeding days in recent studies 8
POPs reduce menstrual blood loss comparably to COCs but with more favorable side effect profiles (less nausea, headaches, weight gain) 8. However, irregular bleeding patterns are more common initially.
Fourth-Line: Depot Medroxyprogesterone Acetate (DMPA, Depo-Provera®)
DMPA injections every 3 months can reduce heavy bleeding, with amenorrhea common after ≥1 year of use 4. However, irregular bleeding and spotting are common initially, requiring enhanced counseling about expected patterns 4.
Management of breakthrough bleeding with DMPA:
- NSAIDs for 5-7 days during bleeding episodes
- Short-term hormonal treatment with COCs or estrogen for 10-20 days (if medically eligible) 4
Adjunctive Pain Management
For dysmenorrhea (painful periods) regardless of contraceptive choice:
NSAIDs are first-line for pain:
- Mefenamic acid 500 mg three times daily for 5 days
- Naproxen 500 mg twice daily
- Ibuprofen 400-800 mg three times daily
- Start at onset of bleeding or pain 4, 9
NSAIDs reduce prostaglandin production, directly addressing the mechanism of menstrual pain and reducing blood loss 10.
Clinical Algorithm
- First choice: Offer LNG-IUS (Mirena®) - most effective for both heavy bleeding and pain
- If LNG-IUS declined or contraindicated: Prescribe COCs, preferably estradiol valerate/dienogest (Natazia®) or standard low-dose COCs
- If estrogen contraindicated: Use progestin-only pills or DMPA
- Add NSAIDs for breakthrough pain or bleeding episodes
- If bleeding persists after 3-6 months: Evaluate for underlying pathology (fibroids, polyps, adenomyosis, bleeding disorders) before switching methods 4
Common Pitfalls to Avoid
- Don't dismiss irregular bleeding in the first 3-6 months - this is expected with LNG-IUS and implants and typically improves. Enhanced counseling about expected patterns reduces discontinuation 4
- Don't use aspirin for menstrual bleeding - it may increase blood loss 4
- Don't prescribe third-generation COCs or drospirenone-containing COCs as first-line - they carry higher VTE risk than second-generation formulations 3
- Don't forget contraceptive counseling - while treating bleeding, ensure patients understand contraceptive efficacy and proper use of their chosen method 11